RepligenRGEN +1.14%83 Days Payable is 34.32 as of Mar. 2026, which is 2% above its 10-year median of 33.59. GuruFocus rates RGEN with a GF Score™ of 83/100 and a GF Value™ of $175.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Repligen ranks worse than 85.53% on this metric.
Repligen's average Accounts Payable for the
three
months ended in Mar. 2026 was $32.3 Mil. Repligen's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $86.0 Mil.
Hence, Repligen's Days Payable for the
three
months ended in Mar. 2026 was 34.32.
The historical rank and industry rank for Repligen's Days Payable or its related term are showing as below:
RGEN'
s Days Payable Range Over the Past 10 Years
Min: 24.3 Med: 33.59 Max: 45.65
Current: 29.77
During the past 13 years, Repligen's highest Days Payable was 45.65. The lowest was 24.30. And the median was 33.59.
RGEN's Days Payable is ranked worse than 85.53% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs RGEN: 29.77
Repligen's Days Payable
declined
from Mar. 2025 (34.64) to Mar. 2026 (34.32).
It may suggest that Repligenaccelerated paying its suppliers.
Repligen Days Payable Related Terms
Repligen Days Payable Historical Data
* Premium members only.
The historical data trend for Repligen's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Repligen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Days Payable distribution charts can be found below:
* The bar in red indicates where Repligen's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Repligen's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repligen (RGEN) has a Days Payable of 34.32 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Repligen and its competitors. This is near median its historical median of 33.59. Over the past decade, Repligen's Days Payable has ranged from 24.30 to 45.65. According to the industry distribution chart, Repligen ranks #680 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 85.5%.
Is Repligen's Days Payable too high?
Repligen's current Days Payable of 34.32 is near median its 10-year median of 33.59. Over the past 10 years, this metric has ranged from a low of 24.30 to a high of 45.65. The Medical Devices & Instruments industry median Days Payable is 67.87. Repligen's value of 34.32 is 49.4% below this industry median. Based on the distribution chart, Repligen ranks #680 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Repligen has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Days Payable compare to ATR and AVTR?
According to the Medical Devices & Instruments industry distribution chart, Repligen ranks #680 out of 795 companies for Days Payable. This places Repligen in the lower half of its industry. The industry median Days Payable is 67.87. Repligen's value of 34.32 is 49.4% below this benchmark. Historically, Repligen's own Days Payable has ranged from 24.30 to 45.65 over the past decade. While the company's 10-year median is 33.59 vs. the industry median of 67.87, Repligen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Repligen's current Days Payable of 34.32 is 49.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Repligen and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repligen's current Days Payable is 34.32, which is near median its own 10-year median of 33.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $175.89, compared to a current price of $146.97 — trading 16.4% below its estimated fair value. The current Days Payable is 34.32, which is near median its 10-year median of 33.59 and 49.4% below the Medical Devices & Instruments industry median of 67.87. Repligen's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Repligen (RGEN), the current Days Payable is 34.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repligen (RGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Repligen stock appears to be undervalued.
The current stock price of $146.97 is trading 16.4% below its estimated GF Value™ of $175.89.
GuruFocus considers Repligen to be Modestly Undervalued.
Key valuation signals for RGEN:
Days Payable: 34.32 (near median its 10-year median of 33.59)
GF Value™: $175.89 vs. price of $146.97 (16.4% below fair value)
Industry Position: 49.4% below the Medical Devices & Instruments median (#680 of 795)
No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
83GF Score
Get the complete analysis for RGEN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEN has been successfully added to your 
